Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420717 | 0.98 | CA12 (0.54) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL18912608 | 0.89 | MAPK1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18231989 | 0.87 | MAPK1 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL28719503 | 0.85 | MEN1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL22343645 | 0.85 | HDAC2 (0.49) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL793119 | 0.84 | MEN1 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3366797 | 0.84 | MAPK1 (0.41) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL730168 | 0.84 | HSD17B10 (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2710850 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL665042 | 0.81 | CA12 (0.50) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1504044-A2 | CORE-SHELL POLYMERIC COMPOSITIONS | MEADWESTVACO CORPORATION, Law Department (US) | 2005-02-09 | — | — | EP | claimed |
| US-6767638-B2 | Core-shell polymeric compositions | MEADWESTVACO CORPORATION | 2004-07-27 | — | — | US | claimed |
| WO-2003097709-A2 | CORE-SHELL POLYMERIC COMPOSITIONS | MEADWESTVACO CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030215604-A1 | Core-shell polymeric compositions | WESTVACO CORPORATION (US) | 2003-11-20 | — | — | US | claimed |
| CN-107429154-B | Improved poly (vinyl caprolactam) kinetic gas hydrate inhibitors and methods of making the same | 亨斯迈石油化学有限责任公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20200171214-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-3648806-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | Drei Lilien PVG GmbH & Co. KG (DE) | 2020-05-13 | — | — | EP | disclosed |
| CN-104744446-B | Heteroaryl compound and its application in drug | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| WO-2019008192-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2019-01-10 | — | — | WO | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| US-4112207-A | Radiation-curable polymers bearing quaternary nitrogen groups | THE DOW CHEMICAL COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | CA12 1571/4885CA1 1051/4885CA2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.